BRIEF-Kamada meets primary endpoint of U.S. Phase 2 study of inhaled Alpha-1 Antitryp
 

BRIEF-Kamada meets primary endpoint of U.S. Phase 2 study of inhaled Alpha-1 Antitrypsin
* Kamada meets primary endpoint of U.S. Phase 2 study ofinhaled Alpha-1 Antitrypsin for the treatment of Alpha-1Antitrypsin deficiencyhttp://feeds.feedburner.com/~ff/reut...?d=yIl2AUoC8zA http://feeds.feedburner.com/~ff/reut...aE:V_sGLiPBpWU http://feeds.feedburner.com/~ff/reut...aE:F7zBnMyn0Lo
http://feeds.feedburner.com/~r/reute...~4/KflT2BmSuN0